INmune Bio, Inc.
INMB
Rank in Stocks
#24676
INmune Bio, Inc. is a clinical-stage biotechnology company focused on... INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Share Price
$1.13
Last synced: 2026-11-09
Market Cap
$31.36M
Change (1 day)
0.00%
Change (1 year)
-25.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade INmune Bio, Inc. (INMB)
Category
Healthcare
Operating Margin for INmune Bio, Inc. (INMB)
Operating Margin as of November 2026 TTM: 0.00%
According to INmune Bio, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -61,738.00%.
Operating Margin history for INmune Bio, Inc. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -61,738.00% | -79.73% |
| 2024 | -304,535.71% | 1,487.14% |
| 2023 | -19,187.74% | 176.53% |
| 2022 | -6,938.77% | -56.92% |
| 2021 | -16,106.63% | -85.51% |
| 2020 | -111,163.64% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about INmune Bio, Inc.'s operating margin
What was INmune Bio, Inc.'s operating margin in 2025?
In 2025, INmune Bio, Inc.'s operating margin was -61,738.00%, compared with -304,535.71% in 2024.
How has INmune Bio, Inc.'s operating margin changed since 2020?
From 2020 to 2025, INmune Bio, Inc.'s operating margin was highest in 2022 (-6,938.77%) and lowest in 2024 (-304,535.71%).
How does INmune Bio, Inc.'s operating margin compare with similar companies?
INmune Bio, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.